All news

PharmaCyte Biotech announces 1-for-19 reverse stock split

Alpha Vantage · Investing News Network · · AI-summarised by FinFlash

PharmaCyte Biotech announced a 1-for-19 reverse stock split to raise its per-share price and regain compliance with Nasdaq's minimum bid price requirement. The consolidation reduces outstanding common shares from roughly 10.7 million to 566,087. For investors, this adjustment maintains the company's listing eligibility while leaving underlying equity ownership unchanged.

Read original source

PMCB company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.